AstraZeneca CEO responds for the first time to Chinese executive detention: Wang Lei is discussing with lawyer
六月清晨搅
发表于 2024-11-13 15:41:21
131
0
0
On November 12th local time, Pascal Soriot, the global CEO of AstraZeneca, publicly responded for the first time to the detention of Wang Lei, the company's China regional president. Suboko said, "Wang Lei is discussing with his lawyer, and the company does not have any new information about the case
Suboko made the above response after the release of AstraZeneca's third quarter financial report. He also said, "We attach great importance to the issues in the Chinese market and are taking measures to further strengthen compliance
However, he denied that AstraZeneca headquarters lacked supervision over compliance. He said that the company has over 16000 employees in China, unfortunately some people may be tempted to maximize sales.
He also stated that AstraZeneca has strengthened its compliance team of over 200 people in China and introduced resident compliance officers to use artificial intelligence to review sales personnel's expense reports and monitor any inappropriate behavior.
It is worth noting that on November 12th, the National Health Commission held a symposium for pharmaceutical companies, inviting Chinese and foreign-funded enterprises to participate together. The content emphasized at the meeting also included "compliant marketing" and other aspects.
According to industry insiders, on the second day after AstraZeneca announced that Wang Lei was under investigation, executives from the company's headquarters went to China to handle related issues, but the specific negotiation content is unknown.
Subobo emphasized that the company remains committed to the Chinese market for a long time, and its previous plan to build a $450 million factory in China has not changed yet. He also stated that AstraZeneca has never publicly discussed the option of splitting its Chinese business.
AstraZeneca released better than expected third quarter financial report on November 12th and raised its annual sales and profit expectations. According to the financial report, AstraZeneca's third quarter revenue reached $13.6 billion. Among them, sales in the China region increased by 15% to 1.7 billion US dollars, accounting for approximately 12% of the company's total revenue.
The company claims that this is due to strong demand for its oncology and rare disease drugs. In the third quarter, AstraZeneca's oncology division saw a 21% increase in sales to $5.6 billion, accounting for over 40% of total revenue. The two drugs that have made significant contributions to the growth of AstraZeneca's oncology drug division are Tagrisso and Enhertu.
However, since the end of last month, AstraZeneca's stock price has fallen by over 10%, mainly due to the uncertainty faced by the company's China business.
On the evening of October 30th, AstraZeneca announced that its CEO in China, Wang Lei, is currently under investigation. On November 6th, AstraZeneca held a temporary investor meeting to disclose the latest developments regarding Wang Lei's "detention". However, AstraZeneca emphasized that the relevant Chinese departments are currently only investigating individual executives of the company and do not involve the company's business.
According to the latest disclosure by AstraZeneca at its investor meeting on November 6th, in addition to Wang Lei, the company has two current and former executives under investigation for illegal imports of drugs from Hong Kong to mainland China.
The first financial reporter learned from an institutional investor that AstraZeneca also emphasized that although China has always been the company's main growth driver, growth has slowed down. The company reminds investors that the profit margin in the Chinese market is limited by some regional specific factors, including approval time, national medical insurance catalog negotiations, centralized volume based procurement, and the increase in sales and marketing expenses related to drugs.
At the same time, AstraZeneca is increasing its investment in the US market. The company recently announced that it will invest $2 billion to expand the construction of factories for research and production of biopharmaceuticals and cell therapies in the United States. Subobo stated that the company "supports the United States' leadership in healthcare innovation" and strengthens the development of cutting-edge therapies.
AstraZeneca now expects its total investment in the United States to reach $3.5 billion by the end of 2026, with new investments located in production bases in Maryland, Texas, and California.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- IPhone 16 official first price reduction across all models: up to 1600 yuan cheaper
- Is Apple also worried about sales? IPhone 16 series official first price reduction promotion after just over a month of release
- BeiGene executive Yin Min is under investigation after previously serving at AstraZeneca | News
- Johnson&Johnson launches the "No Silver in This Place" public welfare project, focusing for the first time on fair academic and professional development for psoriasis patients
- Reddit achieves profitability for the first time, with stock price soaring by 25%
- Est é e Lauder appoints new CEO, two third-generation heirs resign, and for the first time in 75 years, no family members participate in management
- NetEase refutes rumors: executive corruption case involving money laundering is untrue
- For the first time in history! Bitcoin breaks through the $80000 mark and rises 4% within the day
- Why did the stock price of Bilibili, which achieved profitability for the first time in the quarter, fall by more than 13%?
- Depth | From relying on games to relying on games again, Bilibili disguises itself as a community and makes its first "atypical" profit
-
アリババは、26億5000万ドルのドル建て優先無担保手形と170億元の人民元建て優先無担保手形の定価を発表した。ドル債の発行は2024年11月26日に終了する予定です。人民元債券の発行は2024年11月28日に終了する予定だ ...
- SOGO
- 前天 09:05
- 支持
- 反对
- 回复
- 收藏
-
スターバックスが中国事業の株式売却の可能性を検討していることが明らかになった。 11月21日、外国メディアによると、スターバックスは中国事業の株式売却を検討している。関係者によると、スターバックスは中国事 ...
- 献世八宝掌
- 昨天 16:29
- 支持
- 反对
- 回复
- 收藏
-
【意法半導体CEO:中国市場は非常に重要で華虹と協力を展開】北京時間11月21日、意法半導体(STM.N)は投資家活動の現場で、同社が中国ウェハー代工場の華虹公司(688347.SH)と協力していると発表した。伊仏半導体 ...
- 黄俊琼
- 昨天 14:29
- 支持
- 反对
- 回复
- 收藏
-
【ナスダック中国金龍指数は1%下落した。人気の中概株の多くは下落した】現地時間11月21日、ナスダック中国金龍指数は1%下落し、人気の中概株の多くは下落し、必死に10%超下落し、愛奇芸は7%超下落し、百度は6%近く ...
- 比尔992
- 半小时前
- 支持
- 反对
- 回复
- 收藏